Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe criteria for selecting optimal first-line therapy in HBeAg-positive patients
- Discuss strategies for managing resistance in HBeAg-positive patients
- Recount data regarding the optimal duration of treatment and posttreatment monitoring strategies in HBeAg-positive patients
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.